Biomerica(BMRA) - 2025 Q3 - Quarterly Report

Financial Performance - Consolidated net sales for the three months ended February 28, 2025, were approximately $1,119,000, a 10$1,017,000 for the same period in 2024[45] - For the nine months ended February 28, 2025, consolidated net sales were approximately $4,562,000, compared to$4,299,000 for the same period in 2024, reflecting a 6% increase[45] - Total revenue for the three months ended February 28, 2025, was $1,119,000, an increase from$1,017,000 for the same period in 2024, representing a growth of approximately 10%[87] - North America generated $404,000 in revenue for the three months ended February 28, 2025, compared to$393,000 in 2024, reflecting a growth of about 2.8%[87] - Asia's revenue increased significantly to $365,000 in the three months ended February 28, 2025, from$210,000 in 2024, marking a growth of approximately 73.8%[87] Financial Position - As of February 28, 2025, the company had cash and cash equivalents of approximately $3,058,000 and an accumulated deficit of approximately$52 million[29] - As of February 28, 2025, total gross receivables were approximately $1,293,000, with key customers accounting for 76$55,000 in advances from domestic customers as of February 28, 2025, representing prepayments on future shipments[70] - The Company has total minimum future lease payments of $569,000 as of February 28, 2025, with an imputed interest of$26,000[93] Operating Results - The company incurred net losses and negative cash flows from operations, indicating ongoing financial challenges[29] - Research and development costs were approximately $217,000 for the three months ended February 28, 2025, down from$343,000 for the same period in 2024[73] - Share-based compensation expenses related to stock options were approximately $91,000 for the three months ended February 28, 2025, compared to$340,000 for the same period in 2024[65] - Advertising costs were approximately $4,000 for the three months ended February 28, 2025, compared to$25,000 for the same period in 2024[76] Stock Transactions - The company sold 3,333,333 shares of common stock at a gross sales price of $2.40 per share, resulting in net proceeds of approximately$7,300,000 after deducting issuance fees[34] - During the nine months ended February 28, 2025, the company sold 3,525,359 shares at prices ranging from $0.36 to$1.04, generating net proceeds of approximately $2,015,000[37] - The Company sold 3,525,359 shares of common stock during the nine months ended February 28, 2025, resulting in gross proceeds of approximately$2,143,000[86] Asset Management - The Company invested approximately $165,000 into a privately held Polish distributor, owning about 6$25,000 for credit losses as of February 28, 2025[52] - Inventory reserves were approximately $422,000 as of February 28, 2025, down from$467,000 as of May 31, 2024[55] - As of February 28, 2025, the Company had approximately $475,000 of gross inventory located in Mexicali, Mexico[87] Lease Obligations - The total lease cost for the nine months ended February 28, 2025, was$280,000, slightly down from $283,000 in the same period of 2024[92] - Cash paid for operating lease liabilities was$274,000 for the nine months ended February 28, 2025, compared to $267,000 for the same period in 2024[93] - The weighted-average remaining lease term decreased to 1.06 years as of February 28, 2025, from 2.77 years in the previous year[93] - The Company operates a facility in Irvine, California, with a lease expiring in August 2026, and has the option to extend for an additional five years[89] Legal Matters - There were no material legal proceedings pending as of February 28, 2025, indicating a stable legal environment for the Company[95] Intangible Assets - The Company did not identify any indicators of impairment for intangible assets during the nine months ended February 28, 2025[60] - Amortization expense for intangible assets was approximately$5,000 for the three months ended February 28, 2025, compared to $4,000 for the same period in 2024[59] - The Company recognized a net operating loss that generated deferred tax assets for NOL carryforwards, establishing a full valuation allowance against these deferred tax assets as of February 28, 2025[74]